KLK9 Inhibitors

Chemical inhibitors of KLK9 utilize a variety of mechanisms to impede the protease's function. AEBSF is known to bind irreversibly to the serine residue within KLK9's active site, thus rendering the protease inactive. This covalent modification ensures that the enzyme cannot partake in its typical substrate cleavage, directly inhibiting its action. Similarly, 3,4-Dichloroisocoumarin functions by covalently modifying the serine residue within the active site of KLK9, leading to a blockage of its enzymatic activity. On the other hand, Aprotinin and Antipain exert their inhibitory effects by likely binding to KLK9's active site in a manner that prevents substrate access, subsequently blocking proteolytic activity. Leupeptin interacts with KLK9 by reversibly binding to the active site, which also prevents the enzyme from engaging in proteolytic cleavage of its substrates. Additionally, Chymostatin can bind to the active site of KLK9, impeding its proteolytic activity by physically obstructing substrate interaction. Gabexate mesylate and Nafamostat mesylate inhibit KLK9 by competitively inhibiting the active site, which means that these inhibitors mimic the structure of the natural substrates and bind to the enzyme in their place, preventing actual substrates from being processed. Sivelestat functions in a similar fashion by occupying the active site of KLK9, thus preventing substrate cleavage. In contrast, E-64 targets KLK9 by forming a covalent bond with the active cysteine residue, which irreversibly inactivates the enzyme. Phosphoramidon takes a different approach by chelating the zinc ion within the active site of KLK9, an ion that is essential for the catalytic activity of the protease, thereby inhibiting its function. Although Pepstatin A is more commonly associated with aspartic proteases, it can bind to the protease domain of KLK9 in a non-specific manner, which may result in inhibition of KLK9's proteolytic activity.